1. 6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma. (December 2022) Authors: Reijers, ; Dimitriadis, P.; Traets, J.J.; Saw, R.; Versluis, J.M.; Pennington, T.; Kapiteijn, E.; Van der Veldt, A.A.M.; Suijkerbuijk, K.; Hospers, G.; Van Houdt, W.; Broeks, A.; Cornelissen, S.; Spillane, A.; Scolyer, R.; van de Wiel, B.; Menzies, A.M.; van Akkooi, A.C.J.; Long, G.V.; Blank, C.U. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗